Pharma Industry News

A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

yahoo.com - Jeff Lewis - Ascendis Pharma (ASND) to List Ordinary Shares Directly on Nasdaq
Ascendis Pharma (ASND) to List Ordinary Shares Directly on Nasdaq
Yahoo!

Ascendis Pharma A/S (NASDAQ:ASND) is one of the 7 Best Strong Buy European Stocks to Invest In. On April 8, 2026, Ascendis Pharma A/S (NASDAQ:ASND) announced plans to list its ordinary shares directly on The Nasdaq Global Select Market, effective…

globenewswire.com - Nxera Pharma - Nxera Pharma's Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia
Nxera Pharma's Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia
GlobeNewswire

NBI-1117570 is an investigational oral, dual muscarinic M1/M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with Neurocrine Nxera to receive US$22.5 million in milestone…

axios.com - Peter Sullivan - Pharma tariffs force biotech to weigh price deals
Pharma tariffs force biotech to weigh price deals
Axios

The threat of new tariffs on drugmakers has set off a debate within the biotech industry over whether to cut voluntary pricing deals with the Trump administration in exchange for exemptions. Why it matters: Small and midsize companies don't have…

republicworld.com - Nitin Waghela - Torrent Pharma Share Price Surges Nearly 2% After This USFDA Update
Torrent Pharma Share Price Surges Nearly 2% After This USFDA Update
Republic World

The shares of Torrent Pharma surged nearly 2% to hit an intra-day high of Rs 4210 apiece on Monday, April 13 after the USFDA inspection of its Bileshwarpura (Oncology) facility concluded with zero observations. According to the company bourse…

fool.com - Jack Delaney - Which Dividend Pharma Stock Should a Value Investor Choose Today?
Which Dividend Pharma Stock Should a Value Investor Choose Today?
The Motley Fool

The pharmaceutical sector has a reputation for offering high-growth opportunities, but is also known for being risky. However, there's more to that sector than meets the eye. There are pharmaceutical companies that can fit into a value investor's…

cnbc.com - Anniek Bao - CNBC Daily Open: Trump goes from opening the Strait of Hormuz to blockading it
CNBC Daily Open: Trump goes from opening the Strait of Hormuz to blockading it
CNBC

Trump ordered the U.S. Navy to blockade the Strait of Hormuz from 10 a.m. ET on Monday. U.S.-Iran talks broke down without a deal. Brent, WTI rose sharply; Asian stocks fell in early trade. American consumer confidence in April plunged to a record…

marketbeat.com - BTIG Research Reaffirms 'Buy' Rating for Ascentage Pharma Group International (NASDAQ:AAPG)
BTIG Research Reaffirms 'Buy' Rating for Ascentage Pharma Group International (NASDAQ:AAPG)
MarketBeat

Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report)'s stock had its 'buy' rating reissued by BTIG Research in a note issued to investors on Monday, Benzinga reports. They presently have a $48.00 target price on the stock. BTIG…

marketbeat.com - Baillie Gifford & Co. Sells 363,734 Shares of Royalty Pharma PLC $RPRX
Baillie Gifford & Co. Sells 363,734 Shares of Royalty Pharma PLC $RPRX
MarketBeat

Baillie Gifford & Co. trimmed its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 2.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 17,008,768…

marketbeat.com - Nuvectis Pharma, Inc. $NVCT Shares Acquired by Iridian Asset Management LLC CT
Nuvectis Pharma, Inc. $NVCT Shares Acquired by Iridian Asset Management LLC CT
MarketBeat

Iridian Asset Management LLC CT increased its holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) by 44.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned…

thehindubusinessline.com - Strengthening R&D, investment key for Indian drugmakers to lead globally: Nadda
Strengthening R&D, investment key for Indian drugmakers to lead globally: Nadda
BusinessLine

India is best positioned to play a leading role as the global pharmaceutical landscape evolves with increasing emphasis on biologics, biosimilars and specialty medicine, for which strengthening R&D, increased investment and deeper industry…

rediff.com - Nandita Malik - US-Iran Negotiations Collapse: Global Markets Dive, Crude Oil Prices Soar
US-Iran Negotiations Collapse: Global Markets Dive, Crude Oil Prices Soar
Rediff.com

Global stock markets, including India's Sensex and Nifty, plunged significantly as the failure of US-Iran peace negotiations sparked fears of a prolonged conflict and sent crude oil prices soaring. Indian equity benchmarks Sensex and Nifty…

adweek.com - Mark Ritson - The Cockroach of Marketing Concepts Will Never Die
The Cockroach of Marketing Concepts Will Never Die
ADWEEK

Ready to move from account support to strategic lead? The ADWEEK MiniMBA in Marketing gives you the credentials and confidence to step up. Learn how. In 1898, a young Philadelphia ad man named Elias St. Elmo Lewis wrote something that would outlast…

dailymail.co.uk - Muiris Ó Cearbhaill - Drug makers to pay higher charges - and guess who'll foot the bill
Drug makers to pay higher charges - and guess who'll foot the bill
Mail Online

DRUG manufacturers have been hit with higher charges to help fund our medicines watchdog – and the cost is expected to be passed on to consumers. Records released to the Mail reveal Health Minister Jennifer Carroll MacNeill approved the…

afaqs.com - afaqs! news bureau - Scribbld bags digital mandate for Brushers Co
Scribbld bags digital mandate for Brushers Co
afaqs!

Independent marketing agency Scribbld has secured the digital mandate for oral care brand Brushers Co. The mandate will be managed from Scribbld's Mumbai office and covers the brand's go-to-market strategy across pre-launch, launch, and post-launch…

yahoo.com - Jeff Lewis - BofA Raises its Price Target on Teva Pharmaceutical (TEVA) to $42
BofA Raises its Price Target on Teva Pharmaceutical (TEVA) to $42
Yahoo!

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the 8 Cheap Large Cap Stocks to Buy Now. On April 9, 2026, BofA raised the price target on Teva Pharmaceutical Industries Limited (NYSE:TEVA) to $42 from $38 and maintained a Buy rating.

Receive a Daily briefing on Pharma Industry News

Get Started